CAFE Comparison of Atypicals in First Episode of Psychosis - Full Text View

Sponsor:	AstraZeneca
Collaborator:	University of North Carolina
Information provided by:	AstraZeneca
ClinicalTrials.gov Identifier:	NCT00034892

Purpose

The purpose of this study is to compare the effectiveness, tolerability, and efficacy of the currently available atypical antipsychotic drugs olanzapine (2.5-20 mg/day), quetiapine (100-800 mg/day) and risperidone (0.5-4 mg/day) in patients with schizophrenia, schizophreniform disorder, or schizoaffective disorder who are experiencing their first psychotic episode.

Condition	Intervention	Phase
Schizophrenia Psychotic Disorders Mental Health Mental Disorders	Drug: Olanzapine, risperidone	Phase IV

Study Type:	Interventional
Study Design:	Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study
Official Title:	Efficacy and Tolerability of Olanzapine, Quetiapine and Risperidone in the Treatment of First Episode Psychosis: A Randomized Double Blind 52-Week Comparison

Resource links provided by NLM:

MedlinePlus related topics: Child Mental Health Mental Health Psychotic Disorders Schizophrenia

Drug Information available for: Risperidone Olanzapine

U.S. FDA Resources

Eligibility

Ages Eligible for Study:	16 Years to 40 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Patients must meet criteria for schizophreniform disorder, schizophrenia, or schizoaffective disorder with psychotic symptoms lasting 1-60 months
Psychotic symptoms must have persisted at least one month, and not more thn 5 years (60 months)
Patients must have no previous history of drug treatment (greater than a total of 16 weeks) with antipsychotics

Exclusion Criteria:

Patients with history of psychotic disorder with recovery period of at least 3 months
Female patients who are pregnant or nursing
Patients with a known history of mental retardation

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00034892

Hide Study Locations

Locations

United States, California

Stanford, California, United States
United States, Florida

Miami, Florida, United States
United States, Georgia

Atlanta, Georgia, United States

Augusta, Georgia, United States
United States, Illinois

Chicago, Illinois, United States
United States, Louisiana

Shreveport, Louisiana, United States
United States, Massachusetts

Boston, Massachusetts, United States

Worcester, Massachusetts, United States
United States, Minnesota

Minneapolis, Minnesota, United States
United States, Missouri

St. Louis, Missouri, United States
United States, Nevada

Las Vegas, Nevada, United States
United States, New York

Brooklyn, New York, United States

New York, New York, United States
United States, North Carolina

Charlotte, North Carolina, United States

Butner, North Carolina, United States

Chapel Hill, North Carolina, United States
United States, Ohio

Kettering, Ohio, United States

Cincinnati, Ohio, United States

Cleveland, Ohio, United States
United States, Pennsylvania

Philadelphia, Pennsylvania, United States
United States, Texas

Conroe, Texas, United States

San Antonio, Texas, United States
Research Site
Dallas, Texas, United States
United States, Utah

Salt Lake City, Utah, United States
Canada, Alberta

Calgary, Alberta, Canada
Canada, Nova Scotia

Halifax, Nova Scotia, Canada

Sponsors and Collaborators

AstraZeneca

University of North Carolina

More Information

No publications provided by AstraZeneca

Additional publications automatically indexed to this study by National Clinical Trials Identifier (NCT ID):

Perkins DO, Gu H, Weiden PJ, McEvoy JP, Hamer RM, Lieberman JA; Comparison of Atypicals in First Episode study group. Predictors of treatment discontinuation and medication nonadherence in patients recovering from a first episode of schizophrenia, schizophreniform disorder, or schizoaffective disorder: a randomized, double-blind, flexible-dose, multicenter study. J Clin Psychiatry. 2008 Jan;69(1):106-13.

Keefe RS, Sweeney JA, Gu H, Hamer RM, Perkins DO, McEvoy JP, Lieberman JA. Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: a randomized, double-blind 52-week comparison. Am J Psychiatry. 2007 Jul;164(7):1061-71.

McEvoy JP, Lieberman JA, Perkins DO, Hamer RM, Gu H, Lazarus A, Sweitzer D, Olexy C, Weiden P, Strakowski SD. Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison. Am J Psychiatry. 2007 Jul;164(7):1050-60.

Study ID Numbers:	5077IL/0114
Study First Received:	May 2, 2002
Last Updated:	October 12, 2006
ClinicalTrials.gov Identifier:	NCT00034892 History of Changes
Health Authority:	United States: Food and Drug Administration

Additional relevant MeSH terms:

Neurotransmitter Agents
Neurotransmitter Uptake Inhibitors
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Olanzapine
Psychotropic Drugs
Antiemetics
Schizophrenia
Serotonin Antagonists
Pathologic Processes
Mental Disorders
Therapeutic Uses
Psychotic Disorders
Schizophrenia and Disorders with Psychotic Features

Disease
Tranquilizing Agents
Gastrointestinal Agents
Risperidone
Central Nervous System Depressants
Dopamine Antagonists
Antipsychotic Agents
Serotonin Uptake Inhibitors
Pharmacologic Actions
Serotonin Agents
Autonomic Agents
Dopamine Agents
Peripheral Nervous System Agents
Central Nervous System Agents

ClinicalTrials.gov processed this record on November 25, 2009